Drug Trial Radar · NCT05455372
Influence of Oral Hp Infection and Oral Related Factors on Gastric Hp Infection and Eradication Therapy
Last checked: Nov 19, 2026Latest source record: Jul 13, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
600
Planned (sponsor's estimate)
Start
Jul 8, 2022
Primary completion
Sep 30, 2023
Study completion Mar 31, 2024
Sponsor
- Lead sponsor
- Second Affiliated Hospital of Xi'an Jiaotong UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 13, 2022
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Helicobacter pylori (H. pylori) is closely related to the occurrence of gastric cancer and other diseases. The discovery and eradication of H. pylori is of great significance for the prevention and treatment of related diseases. Oral H. pylori may act as a "reservoir" to cause H. pylori to spread between populations and to cause individual gastric H. pylori infection and recurrence.Understanding the oral and gastric H. pylori infection and influencing factors of the population can provide scientific basis for the formulation of local H. pylori infection prevention strategies.Analyzing the influencing factors of H. pylori eradication in the population can improve the local H. pylori eradication rate and reduce the recurrence of H. pylori infection.Therefore, this study intends to analyze the influence of oral H. pylori infection and oral related factors on gastric H. pylori infection and eradication therapy in outpatients of a tertiary hospital in Xi'an.
Conditions
- Helicobacter Pylori Infection
Interventions
PPI quadruple therapyDrug
PPI quadruple therapy refers to ilaprazole 5mg + amoxicillin 1000mg + clarithromycin 500mg + colloidal bismuth tartrate 220mg bid.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Oral and gastric H. pylori infection rateTime frame: 1 year
- The affecting factors of oral and gastric H. pylori infection.Time frame: 1 year
- Oral and gastric H. pylori eradication rateTime frame: 1 year
- The affecting factors of gastric H. pylori eradication.Time frame: 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The second affiliated hospital of Xi'an Jiaotong university
Xi'an, Shaanxi, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.